Literature DB >> 16047719

Usefulness of montelukast to prevent adverse reactions to COX-2 selective inhibitors: a case report.

C Serrano1, A Valero, C Picado.   

Abstract

Nonsteroidal anti-inflammatory drug (NSAID)-sensitivity is a frequent condition in patients with chronic urticaria and/or asthma. The physiopatologic process underlying respiratory and cutaneous reactions probably involves an increased production of cysteinyl leukotrienes. Cyclooxygenase 2 (COX-2) selective inhibitor, has been proposed as the main alternative to control pain and inflammatory diseases in these patients. However, a small percentage of patients with NSAID-induced skin reactions does not even tolerate COX-2 selective inhibitors. We report a very infrequent case of a patient with NSAID, paracetamol and COX-2 selective inhibitors sensitivity in whom we induced tolerance to paracetamol and celecoxib using the leukotriene receptor antagonist montelukast prior to oral challenges.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16047719

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  3 in total

1.  Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review.

Authors:  Gabriele Di Lorenzo; Alberto D'Alcamo; Manfredi Rizzo; Maria Stefania Leto-Barone; Claudia Lo Bianco; Vito Ditta; Donatella Politi; Francesco Castello; Ilenia Pepe; Gaetana Di Fede; Giovambattista Rini
Journal:  J Asthma Allergy       Date:  2008-12-09

2.  Montelukast Induces Apoptosis-Inducing Factor-Mediated Cell Death of Lung Cancer Cells.

Authors:  Ming-Ju Tsai; Wei-An Chang; Pei-Hsun Tsai; Cheng-Ying Wu; Ya-Wen Ho; Meng-Chi Yen; Yi-Shiuan Lin; Po-Lin Kuo; Ya-Ling Hsu
Journal:  Int J Mol Sci       Date:  2017-06-24       Impact factor: 5.923

3.  Leukotriene Antagonists in Dermatology.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Dermatol       Date:  2021 Sep-Oct       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.